Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Vivjoa Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Vivjoa (oteseconazole) Coverage Criteria

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Vivjoa to reduce recurrent vulvovaginal candidiasis in eligible patients who are not of reproductive potential and meet specified clinical and prescriber requirements.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVivjoa (oteseconazole) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting recurrent vulvovaginal candidiasis, required fluconazole treatment failure, eligibility status, ruled-out alternative causes, and qualified specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    The 2026 annual review updated the eligible patient criteria.

    4 monthsAuthorization duration
    6 monthsFluconazole maintenance failure
    30 daysSpecified-state fluconazole trial

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RVVC
    Covered indication

    Vivjoa Coverage Criteria

    Initial Vivjoa Authorization

    Vivjoa will be approved when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of recurrent vulvovaginal candidiasis.
    • Patient is not of reproductive potential (i.e., a biological female who is postmenopausal or has another reason for permanent infertility, such as tubal ligation, hysterectomy, or salpingo-oophorectomy), is not pregnant, and is not lactating.
    • BOTH of the following

      • Other causes, including but not limited to bacterial vaginosis or trichomoniasis, have been ruled out.
      • Failure of a maintenance course of oral fluconazole, defined as 100 mg, 150 mg, or 200 mg taken weekly for 6 months.

        For Connecticut, Kentucky, and Mississippi business, only a 30-day trial is required.

    • Prescribed by or in consultation with ONE of the following

      • Infectious disease physician.
      • Obstetrician/Gynecologist.
    • Authorization will be issued for 4 months.

      State mandates may apply. Federal regulatory requirements, member-specific benefit plan coverage, and other policies or utilization management programs may also impact coverage.

    Patients of reproductive potential, patients who are pregnant, and patients who are lactating are not eligible for Vivjoa coverage.

    Initial Therapy

    Initial Therapy Criteria

    Vivjoa will be approved based on all of the following criteria:

    Initial therapy requirements

    • Diagnosis

      • The patient has a diagnosis of recurrent vulvovaginal candidiasis.
    • Eligibility

      • The patient is not of reproductive potential, is not pregnant, and is not lactating.
    • Prior treatment and evaluation

      • Other causes ruled out

    Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Submit an initial prior authorization for Vivjoa before treatment. Authorization requires that all coverage criteria are met, and approval is issued for 4 months.

    • Diagnosis of recurrent vulvovaginal candidiasis.
    • Patient is not of reproductive potential, is not pregnant, and is not lactating.
    • Other causes, including bacterial vaginosis or trichomoniasis, have been ruled out.
    • The patient failed a 6-month maintenance course of oral fluconazole at 100 mg, 150 mg, or 200 mg weekly; for Connecticut, Kentucky, and Mississippi business, only a 30-day trial is required.
    • Prescribed by or in consultation with an infectious disease physician or obstetrician/gynecologist.
    Documentation Required

    Clinical Documentation Required

    Include clinical documentation supporting the diagnosis, reproductive status, exclusion of alternative causes, prior treatment failure, and prescriber qualifications or consultation.

    Clinical Background

    Vivjoa (oteseconazole) is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis. Coverage is intended for females with a history of recurrent vulvovaginal candidiasis who are not of reproductive potential and who meet the policy’s clinical evaluation, prior-treatment, and qualified-prescriber requirements.

    Defined Terms

    Not of reproductive potential
    Biological sexBiological females
    Postmenopausal statusPostmenopausal
    Permanent infertilityAnother reason for permanent infertility, such as tubal ligation, hysterectomy, or salpingo-oophorectomy
    Maintenance course of oral fluconazole
    Dose100 mg, 150 mg, or 200 mg of oral fluconazole
    ScheduleTaken weekly
    Standard duration6 months
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVivjoa (oteseconazole) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documenting recurrent vulvovaginal candidiasis, required fluconazole treatment failure, eligibility status, ruled-out alternative causes, and qualified specialist involvement.
    SourceLink
    On This Page
    Vivjoa Coverage CriteriaInitial TherapyAuthorization and DocumentationClinical BackgroundDefined Terms
    Other causes, including but not limited to bacterial vaginosis or trichomoniasis, have been ruled out.
  1. Fluconazole maintenance failure

    • The patient has failed a maintenance course of oral fluconazole.100 mg, 150 mg, or 200 mg taken weekly for 6 months

      For Connecticut, Kentucky, and Mississippi business, only a 30-day trial is required.

  2. Specialist involvement

    • Prescribed by or in consultation with an infectious disease physician.
    • Prescribed by or in consultation with an obstetrician/gynecologist.
    • Document recurrent vulvovaginal candidiasis.
    • Document that the patient is not of reproductive potential, is not pregnant, and is not lactating; reproductive potential excludes biological females who are postmenopausal or permanently infertile, such as after tubal ligation, hysterectomy, or salpingo-oophorectomy.
    • Document that other causes, including bacterial vaginosis and trichomoniasis, were ruled out.
    • Document the failed oral fluconazole maintenance course, including dose, weekly frequency, and duration.
    • Document prescribing by or consultation with an infectious disease physician or obstetrician/gynecologist.
    Denial Risk

    Failure to Meet Authorization Criteria

    Vivjoa authorization will be denied or remain ineligible when any required criterion is not satisfied or cannot be documented. State mandates, federal regulatory requirements, the member-specific benefit plan, and other utilization management programs may also affect coverage.

    • No documented diagnosis of recurrent vulvovaginal candidiasis.
    • Patient is pregnant, lactating, or of reproductive potential.
    • Alternative causes have not been ruled out.
    • Required oral fluconazole maintenance treatment was not failed, or the applicable trial duration is not met.
    • The prescription is not from, and is not in consultation with, an infectious disease physician or obstetrician/gynecologist.
    • Authorization is requested without the required prior authorization or supporting documentation.
    Business exceptionFor Connecticut, Kentucky, and Mississippi business, only a 30-day trial is required